tiprankstipranks
Trending News
More News >
Cibus (CBUS)
NASDAQ:CBUS
US Market
Advertisement

Cibus (CBUS) AI Stock Analysis

Compare
579 Followers

Top Page

CBUS

Cibus

(NASDAQ:CBUS)

Rating:44Neutral
Price Target:
$1.50
▼(-14.29%Downside)
Cibus faces significant financial challenges, with high debt and negative profitability impacting its financial performance. While there are strategic advancements and some technical interest, the overall financial health and valuation remain weak, leading to a cautious outlook.
Positive Factors
Market Expansion
The recent endorsement by EU member states on the regulation of plants obtained by New Genomic Techniques could eventually translate into an expanded market opportunity for Cibus in Europe.
Regulatory Approvals
The US FDA completed its Plant Biotechnology Consultation Program for the company’s altered lignin alfalfa trait for livestock feed, enabling the commercialization of the plant.
Revenue Growth
Cibus' revenues increased by 135% year-over-year, mainly through collaboration agreements and sales related to developing a palm oil alternative.
Negative Factors
Cash Flow Concerns
A serendipitous opportunity in the form of sustainable ingredients, specifically fermentation based biofragrance products, could somewhat mitigate the company’s need for cash.
Financial Performance
The company produced a net loss of ~$47M, widening over 300% y/y, primarily due to a significant goodwill impairment charge.

Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)

Cibus Business Overview & Revenue Model

Company DescriptionCibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
How the Company Makes MoneyCibus generates revenue through the commercialization of its proprietary gene editing technologies, which are licensed to seed companies and agricultural producers. The company earns money by partnering with these entities to develop crops with enhanced traits, such as increased drought tolerance or pest resistance. These partnerships often involve milestone payments, royalties on sales of seeds and crops developed using Cibus technologies, and research and development collaborations. Additionally, Cibus may engage in strategic alliances to expand its technology applications and market reach, further contributing to its revenue streams.

Cibus Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: -25.53%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant achievements in regulatory milestones and commercial strategy validation, particularly in gene editing and sustainable ingredients. However, financial results showed increased net loss and SG&A expenses, raising concerns about cash burn and profitability.
Q1-2025 Updates
Positive Updates
Commercial Strategy Validation
Cibus, Inc. demonstrated clear validation of its commercial strategy and the transformative potential of its RTDS technology platform, attracting significant commercial interest across rice, canola, and soybean platforms.
Regulatory Milestones
Historic regulatory milestones achieved, including the California Rice Commission's approval for gene-edited rice trials and favorable USDA APHIS designation for canola disease resistance traits.
Sustainable Ingredients Program Progress
Advanced bio-based fermentation bio fragrance products with successful first stage scale-up, anticipating commercialization agreements with consumer packaged goods partners later this year.
Significant Financial Backing
Cibus, Inc. received $21.4 million net proceeds from a registered direct offering in January 2025, with existing cash sufficient to fund planned operating expenses into the third quarter of 2025.
Negative Updates
Increased Net Loss
Net loss for the first quarter of 2025 was $49.4 million, an increase from $27 million in the year-ago period, primarily due to a $21 million non-cash goodwill impairment.
Increased SG&A Expenses
SG&A expense increased to $9.9 million from $7 million in the year-ago period, mainly due to a $3 million litigation accrual.
Cash Burn Concerns
Despite cost-saving initiatives, the company continues to project a net cash burn of around $4 million per quarter.
Company Guidance
During the Cibus, Inc. 2025 Q1 earnings call, the company provided guidance emphasizing its commercial strategy and regulatory advancements. Cibus reported cash and cash equivalents of $23.6 million as of March 31, 2025, with revenue for the first quarter at $1 million, up from $545,000 in the previous year. The net loss was $49.4 million, primarily due to a $21 million non-cash goodwill impairment. Despite this, the company focused on reducing its cash burn rate, targeting a net burn of around $4 million per quarter. Cibus highlighted advancements in its RTDS technology, achieving milestones in rice and canola trait development, and noted significant regulatory progress in Europe and Latin America. The company anticipates nominal revenues from its sustainable ingredients program later in 2025, reflecting its ongoing efforts to optimize operations and maximize shareholder value.

Cibus Financial Statement Overview

Summary
Cibus is struggling with financial difficulties, as highlighted by persistent net losses and negative cash flows. Despite revenue growth, high debt levels and negative profitability margins suggest a precarious financial position. The company must improve operational efficiency and financial management to achieve sustainable growth.
Income Statement
30
Negative
Cibus shows a pattern of increasing revenue in the TTM with a 11.5% growth from the previous annual period. However, the company continues to face significant challenges with profitability, as evidenced by a negative EBIT margin and net profit margin. The gross profit margin is positive, but the overall financial health is weakened by substantial net losses.
Balance Sheet
40
Negative
The company's balance sheet indicates a high debt-to-equity ratio, showing a heavy reliance on debt financing. The return on equity remains negative, reflecting ongoing net losses. However, the equity ratio is relatively stable, suggesting some level of balance sheet strength.
Cash Flow
35
Negative
Cibus has a negative free cash flow, which has deteriorated further in the TTM. The operating cash flow to net income ratio is negative, indicating operational challenges in generating cash. While financing activities provide some cash inflow, the continuous negative free cash flow poses a risk to financial sustainability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.26M1.82M157.00K25.99M23.85M
Gross Profit4.26M1.42M-1.38M-2.57M-11.28M
EBITDA-241.63M-314.58M-15.21M-25.43M-41.53M
Net Income-251.39M-267.63M-16.89M-29.20M-44.84M
Balance Sheet
Total Assets350.07M544.41M22.42M37.19M63.33M
Cash, Cash Equivalents and Short-Term Investments14.43M32.70M3.43M13.82M29.00M
Total Debt36.29M24.62M13.54M17.88M19.76M
Total Liabilities252.24M206.12M15.19M23.06M26.45M
Stockholders Equity92.16M293.47M7.23M14.13M36.88M
Cash Flow
Free Cash Flow-58.85M-50.53M-20.88M-19.31M-45.46M
Operating Cash Flow-58.04M-46.21M-19.36M-18.81M-43.67M
Investing Cash Flow-808.00K55.06M-1.52M11.20M-13.48M
Financing Cash Flow40.60M20.32M9.99M3.74M15.41M

Cibus Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.75
Price Trends
50DMA
1.97
Negative
100DMA
1.98
Negative
200DMA
2.67
Negative
Market Momentum
MACD
-0.03
Negative
RSI
53.54
Neutral
STOCH
73.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Neutral. The current price of 1.75 is above the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.97, and below the 200-day MA of 2.67, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 53.54 is Neutral, neither overbought nor oversold. The STOCH value of 73.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CBUS.

Cibus Risk Analysis

Cibus disclosed 50 risk factors in its most recent earnings report. Cibus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cibus Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$87.10M-31.93%-4.22%18.67%
54
Neutral
$72.22M678.24%-69.59%
52
Neutral
kr5.53B10.86-63.86%2.05%27.22%26.17%
51
Neutral
$53.65M-59.49%21.15%46.44%
46
Neutral
$56.01M-290.21%-100.00%44.28%
44
Neutral
$86.17M-157.73%104.78%40.41%
37
Underperform
$258.25M-141.69%-17.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CBUS
Cibus
1.75
-7.89
-81.85%
AVTX
Avalo Therapeutics
6.67
-5.05
-43.09%
INZY
Inozyme Pharma
4.00
-1.70
-29.82%
KRON
Kronos Bio
0.88
-0.44
-33.33%
GANX
Gain Therapeutics
1.68
0.60
55.56%
MGX
Metagenomi, Inc.
2.38
-2.25
-48.60%

Cibus Corporate Events

Business Operations and Strategy
Cibus Announces Workforce Reduction Strategy
Negative
Jul 23, 2025

On July 21, 2025, Cibus, Inc. announced a reduction in workforce by approximately 34 full-time employees as part of its strategy to streamline business operations and focus on its most immediate and funded commercial opportunities. This move is expected to be completed by December 31, 2025, with the company incurring around $0.5 million in one-time charges for accrued vacation and severance payments in the third quarter of 2025, impacting affected employees who were informed on July 23, 2025.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Private Placements and FinancingRegulatory Filings and Compliance
Cibus Announces Public Offering of Common Stock
Neutral
Jun 6, 2025

On June 5, 2025, Cibus, Inc. entered into Securities Purchase Agreements with various investors, including its Board Chairman, as part of a public offering of 15,714,285 shares of Class A Common Stock. The offering, registered with the SEC, aims to raise funds for developing weed management traits in rice and other corporate purposes. The company has placed restrictions on stock transactions for 60 days post-offering. Additionally, Cibus engaged A.G.P./Alliance Global Partners as the sole placement agent, agreeing to a fee structure based on the proceeds from the sale of shares, with certain exclusions for the Board Chairman’s purchases.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Cibus Announces Strategic Realignment to Streamline Operations
Neutral
Jun 4, 2025

Cibus, Inc. announced a strategic realignment to streamline operations, focusing on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. The company aims to reduce its annual net cash burn to $30 million by 2026 through cost-cutting measures, including rationalizing human capital and non-core facilities. Recent regulatory approvals in the U.S., Ecuador, and India support the company’s gene editing technologies, potentially enhancing its market positioning and facilitating future partnerships. Cibus plans to launch its rice traits commercially in Latin America by 2027-2028, with further expansion planned in the U.S. and Asia.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
Cibus Stockholders Approve 2025 Employee Stock Plan
Positive
May 27, 2025

On May 22, 2025, Cibus, Inc.’s stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the company’s annual meeting. The plan, which was previously approved by the Board of Directors, includes the reservation of 326,384 shares of Class A common stock, with potential for annual increases. This approval marks a significant step in enhancing employee engagement and investment in the company, potentially impacting Cibus’s market position and stakeholder interests.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Cibus Approves Key Measures at Annual Meeting
Neutral
May 23, 2025

On May 22, 2025, Cibus, Inc. held its 2025 Annual Meeting of Stockholders where 64.94% of shares were represented. During the meeting, seven directors were elected, executive compensation was approved, BDO USA, P.C.’s appointment was ratified, and the 2025 Employee Stock Purchase Plan was approved. Additionally, the issuance and repricing of certain warrants, including those held by Rory Riggs, were approved, potentially leading to a change of control under Nasdaq rules.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025